NEW YORK, Nov. 5, 2015 /PRNewswire/ -- OTC Markets
Group Inc. (OTCQX: OTCM), operator of Open, Transparent and
Connected financial markets, today announced Oncolytics Biotech
Inc. (TSX: ONC; OTCQX: ONCY), a Canada-based biotechnology company focused on
the development of oncolytic viruses as potential cancer
therapeutics, has qualified to trade on the OTCQX® Best
Market. Oncolytics previously traded on the NASDAQ Capital
Market.
Logo -
http://photos.prnewswire.com/prnh/20110118/MM31963LOGO
Oncolytics begins trading today on OTCQX under the symbol
"ONCY." U.S. investors can find current financial disclosure
and Real-Time Level 2 quotes for the company on
www.otcmarkets.com.
"Oncolytics is on the cutting edge of cancer innovation,
developing new therapies for the treatment of a wide range of
cancers," said R. Cromwell Coulson,
President and CEO of OTC Markets Group. "We are proud to
welcome this dynamic company to the OTCQX Best Market."
"We are proud to join the impressive and rapidly growing list of
international companies whose shares trade on OTCQX," said Dr.
Brad Thompson, President and CEO of
Oncolytics. "The OTCQX platform offers U.S. investors
convenient trading in Oncolytics' shares in a market that is both
efficient and transparent."
Dorsey & Whitney LLP serves as Oncolytics' Principal
American Liaison ("PAL") on OTCQX, responsible for providing
professional guidance on OTCQX requirements and U.S. securities
laws.
About Oncolytics Biotech Inc.
Oncolytics is a
Calgary-based biotechnology
company focused on the development of oncolytic viruses as
potential cancer therapeutics. Oncolytics' clinical program
includes a variety of later-stage, randomized human trials in
various indications using REOLYSIN®, its proprietary
formulation of the human reovirus. For further information
about Oncolytics, please visit: www.oncolyticsbiotech.com.
About OTC Markets Group Inc.
OTC Markets Group Inc.
(OTCQX: OTCM) operates Open, Transparent and Connected financial
markets for 10,000 U.S. and global securities. Through our
OTC Link® ATS, we directly link a diverse network of broker-dealers
that provide liquidity and execution services for a wide spectrum
of securities. We organize these securities into markets to
inform investors of opportunities and risks: the OTCQX® Best
Market; the OTCQB® Venture Market; and the OTC Pink® Open
Market. Our data-driven platform enables investors to easily
trade through the broker of their choice at the best possible price
and empowers a broad range of companies to improve the quality and
availability of information for their investors. To learn
more about how we create better informed and more efficient
financial markets, visit www.otcmarkets.com.
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and
SEC regulated ATS.
Subscribe to the OTC Markets RSS Feed
Media Contact:
Saskia
Sidenfaden, OTC Markets Group Inc., +1 (212) 896-4428,
saskia@otcmarkets.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/otc-markets-group-welcomes-oncolytics-biotech-inc-to-otcqx-300172894.html
SOURCE OTC Markets Group Inc.